Search research articles
Contact Us
Filters
Showing results (821-830 of 833) with videos related to
Page
of 84
Sort By:
European Urology
|
January 29, 2023
Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial
Loren K Mell, Stephanie L Pugh, Christopher U Jones, et al.
Cancer
|
March 11, 2026
Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma
Lisa A Kachnic, Jennifer Moughan, Theodore S Hong, et al.
British Journal of Cancer
|
December 4, 1998
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group
K Aabo, M Adams, P Adnitt, et al.
The American Journal of Medicine
|
January 3, 2015
Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up
Sami M A Alnasser, Wei Huang, Joel M Gore, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 25, 2019
Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415
Maria Thor, Joseph O Deasy, Rebecca Paulus, et al.
Journal of Medicinal Chemistry
|
December 20, 2019
Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity Target
Zoë A Henley, Augustin Amour, Nick Barton, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 8, 2022
The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521
William A Hall, Theodore G Karrison, Seth A Rosenthal, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 3, 2023
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial
Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
The Lancet. Oncology
|
October 15, 2018
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial
Mack Roach, Jennifer Moughan, Colleen A F Lawton, et al.
European Urology Focus
|
February 2, 2024
Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202
Kimberley S Mak, Molly Scannell Bryan, James J Dignam, et al.
Page
of 84
Search research articles
Search
Showing results (821-830 of 833) with videos related to
Sort By:
Page
of 84
European Urology
|
January 29, 2023
Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial
Loren K Mell, Stephanie L Pugh, Christopher U Jones, et al.
Cancer
|
March 11, 2026
Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma
Lisa A Kachnic, Jennifer Moughan, Theodore S Hong, et al.
British Journal of Cancer
|
December 4, 1998
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group
K Aabo, M Adams, P Adnitt, et al.
The American Journal of Medicine
|
January 3, 2015
Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up
Sami M A Alnasser, Wei Huang, Joel M Gore, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 25, 2019
Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415
Maria Thor, Joseph O Deasy, Rebecca Paulus, et al.
Journal of Medicinal Chemistry
|
December 20, 2019
Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity Target
Zoë A Henley, Augustin Amour, Nick Barton, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 8, 2022
The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521
William A Hall, Theodore G Karrison, Seth A Rosenthal, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 3, 2023
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial
Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
The Lancet. Oncology
|
October 15, 2018
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial
Mack Roach, Jennifer Moughan, Colleen A F Lawton, et al.
European Urology Focus
|
February 2, 2024
Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202
Kimberley S Mak, Molly Scannell Bryan, James J Dignam, et al.
Page
of 84